Scilex Holding (SCLX) Depreciation & Amortization (CF) (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Depreciation & Amortization (CF) of $2.9 million for Q1 2026, up 186.04% year-over-year from $1.0 million in Q1 2025, and up 80.78% on a QoQ basis from $1.6 million in Q4 2025.
Scilex Holding (SCLX) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 186.04% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $6.5 million (up 61.5% YoY), while the FY2025 annual figure was $4.6 million, up 14.26% from the prior year.
- Depreciation & Amortization (CF) came in at $2.9 million for Q1 2026 at Scilex Holding, up from $1.6 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.9 million in Q1 2026, with the low at $944000.0 in Q1 2022.
- Average Depreciation & Amortization (CF) over 5 years is $1.2 million, with a median of $1.0 million recorded in 2024.
- Across the five-year window, Depreciation & Amortization (CF) slipped 3.27% in 2024 and soared 186.04% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then declined by 0.1% to $1.0 million in 2023, then fell by 2.9% to $1.0 million in 2024, then surged by 58.07% to $1.6 million in 2025, then surged by 80.78% to $2.9 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.9 million, $1.6 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 509.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.37 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |